This can be ascribed to the growing cloning approaches in different genetic applications like reproductive cloning and genetic cloning. Additionally, various new product launches in the cloning and mutagenesis market which will demand for cloning and mutagenesis kit along with government organizations are investing for stem cell research for the development of new treatment and therapy have significantly increased the demand for cloning and mutagenesis across different parts of the globe. Additionally, growing geriatric population across the globe which is susceptible to different kinds of diseases and obesity, is further expected to increase the demand for cloning and mutagenesis, thereby fuelling the market growth through 2028. Besides, growing awareness about the advantages of using gene therapy and diagnosis, along with increasing healthcare expenditure on chronic diseases treatment across the globe, are further expected to support the cloning and mutagenesis market during the forecast period. In 2022, an estimated 66,470 people (48,520 men and 17,950 women) will be diagnosed with head and neck cancer in the United States.
Increasing Research and Development Activities in Cancer and Other Chronic Disorders Fueling the Market Growth
Increasing research and development regarding cloning and mutagenesis for the development of cancer therapies and other rare disorders is expected to create a lucrative growth of the market during the forecast period. Government organizations are focusing on developed infrastructure with higher profits. Different type of innovative and ethically accepted therapies found at for cancer therapy along with an increasing development of new products, are expected to boost the market growth over the years. In May 2020, Takara Bio announced a collaboration with AGC Biologics and their businesses will collaborate on a prophylactic DNA vaccine against COVID-19 with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine. . as public-funded research are getting a boost from bodies such as the European Commission and the Japan Agency for Medical Research and Development. In 2020, an estimated 276,480 new cases of invasive breast cancer will be diagnosed in women in the U.S. as well as 48,530 new cases of non-invasive (in situ) breast cancer. The increasing cloning of genes for the synthesis of antibiotics, hormones, and vitamins, among others, for the treatment of issues such as cystic fibrosis, is propelling the market growth.
Increasing Investment by Government Organization is Driving the Market’s Growth
Important factors which are expected to create a lucrative growth of the market include a favourable funding scenario for gene synthesis and cloning services, along with technological advancement in the treatment, followed by research, subcloning services, and rising synergistic activities in the market. Increasing demand for gene therapy and growing adoption of novel and advanced DNA cloning technologies
Market Segmentation
Global cloning & mutagenesis market can be segmented by gene type, by product type, by technique, by application, by end user and by region. Based on gene type, the market can be divided into Standard and Complex. Based on product type, the market can be divided into Cloning Kits and Mutagenesis Kits. Based on technique, the market can be segmented into Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, and Others. Based on application, the market can be segmented into Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, and Others. Based on end user, the market can be differentiated into Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America.
Market Players
Agilent Technologies, Inc., Eurofins Scientific SE, Sartorius AG, Collecta, Inc., Codex DNA Inc., Lonza Group AG, Charles River Laboratories International, Inc., TransGene Biotech Co. Ltd., Takara Bio, Inc., Thermo Fisher Scientific Inc. are some of the leading players operating in the Global Cloning & Mutagenesis Market.
Recent Development
In Jan 2021, Codex DNA and Pfizer signed an early access collaboration and licencing agreement, which will allow Pfizer to use CodexDNA's novel enzymatic DNA synthesis technology in its research and development of mRNA-based vaccines and biotherapies and it will be responsible for further developing the technology.
In May 2020, GenScript just launched a GMP single-strand and double-strand DNA service to aid in the growth of gene and cell therapies. The announcement highlights GenScript's commitment to assisting entire non-viral cell therapy development through the IND-enabling and clinical stages.
·
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · By Therapy · By Indication · By End User · By Region |
| Regional scope | North America; Europe; Asia Pacific; South America; Middle East & Africa |
| Country scope | United States; Canada; Mexico; France; Germany; United Kingdom; Italy; Spain; China; India; Japan; South Korea; Australia; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE |
| Key companies profiled | Agilent Technologies, Inc., Eurofins Scientific SE, Sartorius AG, Collecta, Inc., Codex DNA Inc., Lonza Group AG, Charles River Laboratories International, Inc., TransGene Biotech Co. Ltd., Takara Bio, Inc., Thermo Fisher Scientific Inc. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
